PHAR (Pharming Group) Research & Development: $104.7 Mil (TTM As of Mar. 2026)


PHAR Pharming Group PHAR
79 GF Score
Price $13.27
GF Value $14.23
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pharming Group Research & Development?

Pharming Group PHAR +2.23% 79 Research & Development is $104.7 Mil as of Mar. 2026. GuruFocus rates PHAR with a GF Score™ of 79/100 and a GF Value™ of $14.23 (Fairly Valued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Pharming Group's Research & Development for the three months ended in Mar. 2026 was $25.6 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $104.7 Mil.

Pharming Group  (NAS:PHAR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Pharming Group Research & Development Related Terms

Pharming Group Research & Development Historical Data

* Premium members only.

The historical data trend for Pharming Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group Research & Development Chart

Pharming Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.37 52.53 68.91 83.15 100.37

Pharming Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.14 23.70 23.38 32.10 25.56
PHAR
79GF Score
Pharming Group PHAR
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharming Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $104.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $104.7 Mil mean?
Pharming Group (PHAR) has a Research & Development of $104.7 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Pharming Group and its competitors.
Is Pharming Group's Research & Development too high?
Pharming Group's current Research & Development is $104.7 Mil. Overall, Pharming Group has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Research & Development compare to VRTX and REGN?
Pharming Group's Research & Development of $104.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Pharming Group and its competitors. Pharming Group's current Research & Development is $104.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.23, compared to a current price of $13.27 — trading 6.7% below its estimated fair value. The current Research & Development is $104.7 Mil. Pharming Group's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Pharming Group (PHAR), the current Research & Development is $104.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharming Group (PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of $13.27 is trading 6.7% below its estimated GF Value™ of $14.23. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for PHAR:

  • Research & Development: $104.7 Mil
  • GF Value™: $14.23 vs. price of $13.27 (6.7% below fair value)
  • GF Score™: 79/100 with 1 warning sign

No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
79GF Score

Get the complete analysis for PHAR

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.27
Price
$14.23
GF Value